

# A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

NCT07400653

---

Status	RECRUITING
Phase	Phase 3
Sponsor	Pfizer
Enrollment	999 participants

## Key Eligibility Criteria

---

### Inclusion (10)

- Provision of signed and dated informed consent form (ICF)
- Male or female adults, aged ≥18 years
- Have a BMI at Screening of ≥27.0 kg/m<sup>2</sup>
- Have T2DM for at least 6 months before Screening based on participant reported history or documentation of the disease diagnostic criteria
- Have HbA1c value between ≥6.5% (48 mmol/mol) and ≤10.0% (86.0 mmol/mol) at Screening with stable therapy for at least 90 days prior to Screening/Visit 1. T2DM may be treated with:  
... and 5 more (see full listing online)

### Exclusion (8)

- Female who is breastfeeding, or who is pregnant
- Unwilling or unable to follow contraceptive requirements
- Diagnosis of Type 1 diabetes, or any other types of diabetes except T2DM.
- Severe hypoglycemia and/or hypoglycemia unawareness within the 6 months prior to Screening
- Poorly controlled hypertension  
... and 3 more (see full listing online)

## Locations (184 total)

---

CenExel Anaheim Clinical Trials, Anaheim, California, United States  
Alliance Research Institute, Canoga Park, California, United States  
Core Healthcare Group, Cerritos, California, United States  
... and 181 more locations